MA49357A - Composés, compositions et méthodes permettant de moduler le cftr - Google Patents
Composés, compositions et méthodes permettant de moduler le cftrInfo
- Publication number
- MA49357A MA49357A MA049357A MA49357A MA49357A MA 49357 A MA49357 A MA 49357A MA 049357 A MA049357 A MA 049357A MA 49357 A MA49357 A MA 49357A MA 49357 A MA49357 A MA 49357A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- methods
- modulating cftr
- cftr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562237887P | 2015-10-06 | 2015-10-06 | |
US201662277600P | 2016-01-12 | 2016-01-12 | |
US201662319433P | 2016-04-07 | 2016-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49357A true MA49357A (fr) | 2020-04-22 |
Family
ID=57145069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049357A MA49357A (fr) | 2015-10-06 | 2016-10-06 | Composés, compositions et méthodes permettant de moduler le cftr |
Country Status (17)
Country | Link |
---|---|
US (3) | US10550106B2 (fr) |
EP (1) | EP3359536B1 (fr) |
JP (1) | JP6929276B2 (fr) |
KR (1) | KR20180093882A (fr) |
CN (1) | CN108430994B (fr) |
AU (2) | AU2016336437B2 (fr) |
BR (1) | BR112018007021B1 (fr) |
CA (1) | CA3000483C (fr) |
HK (1) | HK1258811A1 (fr) |
IL (1) | IL258486B (fr) |
MA (1) | MA49357A (fr) |
MX (1) | MX2018004290A (fr) |
NZ (1) | NZ741093A (fr) |
RU (1) | RU2752567C2 (fr) |
SA (1) | SA518391268B1 (fr) |
SG (1) | SG11201802798WA (fr) |
WO (1) | WO2017062581A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2952862A1 (fr) * | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
NZ741093A (en) * | 2015-10-06 | 2022-12-23 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
US20180369209A1 (en) * | 2015-12-22 | 2018-12-27 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
NZ746793A (en) | 2016-04-07 | 2022-10-28 | Proteostasis Therapeutics Inc | Silicone atoms containing ivacaftor analogues |
US20190154661A1 (en) | 2016-05-09 | 2019-05-23 | Proteostasis Therapeutics, Inc. | Methods of identifying cftr modulators |
MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
CA3061476A1 (fr) * | 2017-04-28 | 2018-11-01 | Proteostasis Therapeutics, Inc. | Derives de 4-sulfonylaminocarbonylquinoleine pour accroitre l'activite du cftr |
US20210369749A1 (en) | 2017-10-06 | 2021-12-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
CN107778282B (zh) * | 2017-11-03 | 2020-04-10 | 中山大学 | 喹啉-吲哚衍生物及其在制备治疗阿尔茨海默病的药品中的应用 |
JP2021530465A (ja) | 2018-06-27 | 2021-11-11 | プロテオステイシス セラピューティクス, インコーポレイテッド | プロテアソーム活性増強化合物 |
CN109663129B (zh) * | 2019-02-27 | 2021-05-11 | 四川大学华西第二医院 | 扩张型心肌病治疗药物及其应用 |
EP4119542A1 (fr) * | 2019-11-01 | 2023-01-18 | FMC Corporation | Nouveau procédé efficace de synthèse de 2-amino-5-chloro-n,3-diméthylbenzamide |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
MX2023001993A (es) | 2020-08-20 | 2023-02-27 | Univ Leland Stanford Junior | Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad. |
CN112300009A (zh) * | 2020-10-29 | 2021-02-02 | 山东兴强化工产业技术研究院有限公司 | 一种间苯二胺的制备方法 |
CN112279773B (zh) * | 2020-10-29 | 2022-01-07 | 山东兴强化工产业技术研究院有限公司 | 一种高品质间苯二胺的合成方法 |
CN112142615B (zh) * | 2020-10-29 | 2021-11-23 | 山东兴强化工产业技术研究院有限公司 | 一种异邻苯二甲酰亚胺的制备方法 |
WO2023150236A1 (fr) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol |
WO2023150237A1 (fr) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
WO2023154291A1 (fr) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
CN114436864A (zh) * | 2022-02-17 | 2022-05-06 | 浙江鼎龙科技股份有限公司 | 一种2-甲基-5氨基苯酚的制备方法 |
WO2023224931A1 (fr) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870712A (en) * | 1972-03-17 | 1975-03-11 | Lilly Co Eli | Cinchoninic acid derivatives |
DE3812225A1 (de) | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
US5523408A (en) * | 1994-03-25 | 1996-06-04 | The Dupont Merck Pharmaceutical Company | 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents |
MX9702380A (es) | 1995-08-02 | 1998-02-28 | Uriach & Cia Sa J | Nuevas carboxamidas con actividad antifungica. |
ATE243204T1 (de) | 1995-08-24 | 2003-07-15 | Basf Ag | Isoxazole- und isothiazole-5-carboxamid derivate, deren herstellung und deren verwendung als herbizide |
JP2002505689A (ja) * | 1997-06-19 | 2002-02-19 | セプレイコー インコーポレイテッド | キノリン−インドール抗菌剤、それらに関する用途及び組成物 |
US6207679B1 (en) | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
PT957099E (pt) | 1998-04-15 | 2003-02-28 | Pfizer Prod Inc | Carboxamidas heterociclicas |
WO2002000651A2 (fr) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Inhibiteurs du facteur xa |
DE60137944D1 (de) * | 2000-09-15 | 2009-04-23 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
CA2484209C (fr) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Modulateurs de proteine kinase et procedes d'utilisation |
RU2006115602A (ru) | 2003-10-08 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы переносчиков атф-связывающих кассет |
EP1682127B1 (fr) | 2003-11-14 | 2009-07-29 | Vertex Pharmaceuticals Incorporated | Thiazoles et oxazoles utiles en tant que modulateurs de transporteurs de type cassette de liaison a l'atp |
WO2005077373A2 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Nouveau traitement du reflux gastro-oesophagien pathologique ii |
WO2005077345A1 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Composes pour le traitement de la maladie du reflux gastro-oesophagien |
JP2008503446A (ja) | 2004-05-06 | 2008-02-07 | プレキシコン,インコーポレーテッド | Pde4b阻害剤及びその使用 |
SE0401969D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
JP2006176443A (ja) | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
WO2006136924A1 (fr) | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Antagonistes du recepteur 3 de l'histamine |
WO2007075896A2 (fr) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Inhibiteurs de cytokine heterocycliques |
KR101394245B1 (ko) | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
WO2007086584A1 (fr) | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | NOUVEL INHIBITEUR DE FabK ET DE FabI/K |
TW200815351A (en) | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
WO2008046072A2 (fr) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Inducteurs chimiques de la neurogénèse |
US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
WO2008051757A1 (fr) | 2006-10-20 | 2008-05-02 | Irm Llc | Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr) |
WO2008070739A1 (fr) | 2006-12-06 | 2008-06-12 | Cytokinetics, Inc. | Activateurs de ksp |
WO2009005269A2 (fr) | 2007-06-29 | 2009-01-08 | Sk Holdings Co., Ltd. | Composition pharmaceutique contenant des dérivés d'isoxazole destinée à prévenir et à traiter la resténose |
WO2009011850A2 (fr) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
EP2185530B1 (fr) | 2007-08-02 | 2011-09-14 | N.V. Organon | Dérivés de 5-phenyl-isoxazole-3-carboxamides comme modulateurs de tprv1 |
CN101925603B (zh) * | 2007-12-13 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
WO2009131951A2 (fr) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et procédés comprenant des dérivés isoxazole |
US20090318429A1 (en) | 2008-04-28 | 2009-12-24 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives |
CA2749677A1 (fr) | 2009-02-04 | 2010-08-12 | N.V. Organon | Derives d'isoxazole-5-carboxamide |
KR101748891B1 (ko) | 2009-03-11 | 2017-06-19 | 교린 세이야꾸 가부시키 가이샤 | Gsk-3 억제제로서의 7-시클로알킬아미노퀴놀론 |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
IN2012DN00352A (fr) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
WO2011008931A2 (fr) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés |
US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
ES2603032T3 (es) | 2010-07-15 | 2017-02-23 | Bayer Intellectual Property Gmbh | Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas |
EP2684880B1 (fr) | 2011-03-10 | 2018-02-28 | Daiichi Sankyo Company, Limited | Dérivé de dispiropyrrolidine |
CA2736441A1 (fr) | 2011-04-06 | 2012-10-06 | The Regents Of The University Of California | Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique |
MX350442B (es) | 2011-07-29 | 2017-09-06 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear y usos de los mismos. |
ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
WO2013038373A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyrimidinamides |
US9034879B2 (en) | 2011-09-16 | 2015-05-19 | Novartis Ag | Heterocyclic compounds for the treatment of CF |
WO2013038381A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés d'amide pyridine/pyrazine |
FR2980212A1 (fr) | 2011-09-16 | 2013-03-22 | Agronomique Inst Nat Rech | Augmentation de la recombinaison meiotique chez les plantes par inhibition de la proteine fancm |
US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
UA116628C2 (uk) | 2012-02-16 | 2018-04-25 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб отримання сульфілімінових сполук |
UA110436C2 (en) | 2012-03-06 | 2015-12-25 | Zoetis Llc | Antibacterial phenol compounds |
WO2013146970A1 (fr) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | Nouveau dérivé de quinoléine |
WO2014144860A1 (fr) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Correcteurs agissant par l'intermédiaire de msd1 de la protéine cftr |
WO2014181287A1 (fr) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Composés hétérocyclyliques et leurs utilisations |
CA2915975A1 (fr) | 2013-06-26 | 2014-12-31 | Proteostasis Therapeutics, Inc. | Procedes de modulation de l'activite de cftr |
WO2015051230A1 (fr) | 2013-10-04 | 2015-04-09 | Drexel University | Nouvelles compositions utiles pour inhiber une infection vih-1 et leurs procédés d'utilisation |
EP3116870A1 (fr) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité cftr |
CA2942386A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
US10351527B2 (en) * | 2014-04-09 | 2019-07-16 | The University Of British Columbia | Binding function 3 (BF3) site compounds as therapeutics and methods for their use |
CA2952862A1 (fr) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
WO2016054560A1 (fr) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Composés isoxazoles et procédés pour le traitement de la fibrose kystique |
CA2971855A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derives d'amide 5-(hetero)arylpyrazol-3-carboxylique ou d'amide 1-(hetero)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique |
US10344023B2 (en) | 2014-12-23 | 2019-07-09 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
US10392378B2 (en) | 2014-12-23 | 2019-08-27 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
WO2017040606A1 (fr) | 2015-08-31 | 2017-03-09 | Proteostasis Therapeutics, Inc. | Dérivés d'isoxazole destinés à être utilisés dans le traitement de maladies et de troubles pulmonaires |
NZ741093A (en) | 2015-10-06 | 2022-12-23 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
US20180369209A1 (en) | 2015-12-22 | 2018-12-27 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
NZ746793A (en) | 2016-04-07 | 2022-10-28 | Proteostasis Therapeutics Inc | Silicone atoms containing ivacaftor analogues |
US20190154661A1 (en) | 2016-05-09 | 2019-05-23 | Proteostasis Therapeutics, Inc. | Methods of identifying cftr modulators |
MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
AU2017348183A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating CFTR |
EP3532467A1 (fr) | 2016-10-26 | 2019-09-04 | Proteostasis Therapeutics, Inc. | Composés de pyridazine, compositions et méthodes permettant de moduler cftr |
AU2017348182A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
CA3061476A1 (fr) | 2017-04-28 | 2018-11-01 | Proteostasis Therapeutics, Inc. | Derives de 4-sulfonylaminocarbonylquinoleine pour accroitre l'activite du cftr |
US20200340984A1 (en) | 2017-12-29 | 2020-10-29 | Proteostasis Therapeutics, Inc. | Methods of quantifying cftr protein expression |
-
2016
- 2016-10-06 NZ NZ741093A patent/NZ741093A/en unknown
- 2016-10-06 SG SG11201802798WA patent/SG11201802798WA/en unknown
- 2016-10-06 WO PCT/US2016/055693 patent/WO2017062581A1/fr active Application Filing
- 2016-10-06 CA CA3000483A patent/CA3000483C/fr active Active
- 2016-10-06 BR BR112018007021-1A patent/BR112018007021B1/pt active IP Right Grant
- 2016-10-06 MA MA049357A patent/MA49357A/fr unknown
- 2016-10-06 MX MX2018004290A patent/MX2018004290A/es unknown
- 2016-10-06 RU RU2018116569A patent/RU2752567C2/ru active
- 2016-10-06 US US15/766,667 patent/US10550106B2/en active Active
- 2016-10-06 JP JP2018517564A patent/JP6929276B2/ja active Active
- 2016-10-06 CN CN201680069588.3A patent/CN108430994B/zh active Active
- 2016-10-06 AU AU2016336437A patent/AU2016336437B2/en active Active
- 2016-10-06 KR KR1020187012487A patent/KR20180093882A/ko not_active Application Discontinuation
- 2016-10-06 EP EP16782380.6A patent/EP3359536B1/fr active Active
-
2018
- 2018-04-02 IL IL258486A patent/IL258486B/en unknown
- 2018-04-03 SA SA518391268A patent/SA518391268B1/ar unknown
-
2019
- 2019-01-23 HK HK19101188.9A patent/HK1258811A1/zh unknown
- 2019-12-17 US US16/716,765 patent/US11136313B2/en active Active
-
2020
- 2020-09-18 AU AU2020233776A patent/AU2020233776A1/en not_active Abandoned
-
2021
- 2021-08-25 US US17/411,682 patent/US20220227739A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2018116569A3 (fr) | 2020-02-21 |
AU2020233776A1 (en) | 2020-10-15 |
US20220227739A1 (en) | 2022-07-21 |
EP3359536A1 (fr) | 2018-08-15 |
EP3359536B1 (fr) | 2021-08-04 |
HK1258811A1 (zh) | 2019-11-22 |
IL258486A (en) | 2018-05-31 |
CN108430994A (zh) | 2018-08-21 |
US11136313B2 (en) | 2021-10-05 |
WO2017062581A1 (fr) | 2017-04-13 |
SG11201802798WA (en) | 2018-05-30 |
US20180291006A1 (en) | 2018-10-11 |
US10550106B2 (en) | 2020-02-04 |
CA3000483C (fr) | 2024-02-13 |
AU2016336437B2 (en) | 2020-06-18 |
SA518391268B1 (ar) | 2021-06-08 |
CN108430994B (zh) | 2022-04-12 |
BR112018007021A2 (pt) | 2018-10-16 |
RU2752567C2 (ru) | 2021-07-29 |
NZ741093A (en) | 2022-12-23 |
JP6929276B2 (ja) | 2021-09-01 |
JP2018537413A (ja) | 2018-12-20 |
KR20180093882A (ko) | 2018-08-22 |
IL258486B (en) | 2022-03-01 |
BR112018007021B1 (pt) | 2024-01-09 |
CA3000483A1 (fr) | 2017-04-13 |
US20200385365A1 (en) | 2020-12-10 |
RU2018116569A (ru) | 2019-11-07 |
MX2018004290A (es) | 2018-08-09 |
AU2016336437A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49357A (fr) | Composés, compositions et méthodes permettant de moduler le cftr | |
IL277624A (en) | Preparations for modulation of C9ORF72 expression | |
MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
IL286669A (en) | Compounds and methods for modulating tmprss6 expression | |
HK1245634A1 (zh) | 作為egfr調節劑的取代的2-苯胺基嘧啶衍生物 | |
MA50014A (fr) | Modulateurs de k-ras | |
MA53943A (fr) | Modulateurs de ror-gamma | |
EP3349763A4 (fr) | Composition synthétique de modulation du microbiote | |
MA42061A (fr) | Modulateurs de k-ras | |
EP3199690A4 (fr) | Sèche-linge | |
DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
GB201410693D0 (en) | Splicing modulation | |
FI20155101A (fi) | Nanofibrillaarinen selluloosakoostumus | |
EP3342922A4 (fr) | Séchoir | |
GB201708935D0 (en) | Fibre spreading | |
MA50062A (fr) | Méthodes permettant de traiter la dystrophie musculaire | |
EP3244914A4 (fr) | Méthodes de traitement d'une tauopathie | |
EP3392399A4 (fr) | Séchoir | |
BR112018002225A2 (pt) | dispositivo de dispersão modulado azimutalmente | |
HUE054880T2 (hu) | Lyukacsos háló | |
DK3393238T3 (da) | Dispergeringssammensætning | |
FR3045065B1 (fr) | Peinture bi-composant anti-amiante. | |
IT201600106459A1 (it) | Skistopper per attacchi da scialpinismo | |
CL2016000847S1 (es) | Inversor | |
ES1150609Y (es) | Mechero-caja de color |